The HemOnc Pulse Live at ASH: Naval Daver, MD, on Treating AML in Older Adults, Novel Therapies
By Chadi Nabhan, MD, MBA, FACP, Naval Daver, MD - Last Updated: February 15, 2023Naval Daver, MD, checks in with The HemOnc Pulse, brought to you Blood Cancers Today and the Society of Hematologic Oncology, to discuss treating acute myeloid leukemia in older patients, the emergence of venetoclax, novel therapies, and more, with host Chadi Nabhan, MD, MBA, FACP.
Advertisement
Post Tags:AML ASH 22
Advertisement
Related Posts
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
The Community Oncology Alliance outlined solutions for Congress to address systemic challenges of the U.S. healthcare system.
The investigational small molecule enzomenib has received FDA Orphan Drug and Fast Track designations in AML.
GPC-100 is a a small molecule CXCR4 inhibitor that showed promising preclinical activity in combination with cytarabine.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.